A groundbreaking international study has created the most comprehensive map yet of how our epigenome changes with age. Researchers analyzed DNA methylation patterns across 15,000 samples from 17 different human tissues collected from individuals aged 18 to 100 years. By examining 900,000 methylation sites, this unprecedented study reveals how aging reshapes our epigenetic landscape in both systematic and tissue-specific ways. The research team, including pioneers like Steve Horvath (creator of epigenetic clocks) and Vadim Gladyshev, has compiled what they call "the most complete picture to date" of DNA methylation's relationship with aging.
Two Faces of Epigenetic Aging
DNA methylation denotes the covalent addition of methyl groups to cytosine bases, typically at CpG dinucleotides. This process serves as a critical regulator of gene expression. As we age, this regulatory system becomes disrupted, leading to altered gene expression patterns associated with declining organ function and increased disease susceptibility.
The researchers identified two distinct types of age-related methylation changes:
· Differentially Methylated Positions (DMPs): Sites where methylation changes predictably with age across individuals, representing consistent aging patterns.
· Variably Methylated Positions (VMPs): Sites showing increased methylation variability with age, reflecting individual differences in the aging process.
Additionally, the team measured Shannon entropy to quantify random, stochastic methylation changes. Intriguingly, the same genomic site can exhibit both systematic and random changes, creating a complex mosaic of aging signatures.
· Variably Methylated Positions (VMPs): Sites showing increased methylation variability with age, reflecting individual differences in the aging process.
Additionally, the team measured Shannon entropy to quantify random, stochastic methylation changes. Intriguingly, the same genomic site can exhibit both systematic and random changes, creating a complex mosaic of aging signatures.
Tissue-Specific Methylation Landscapes
The study revealed significant variation in baseline methylation levels across tissues: from 35% in cervical tissue to 63% in the retina. Most tissues showed a clear trend toward hypermethylation with age, which leads to suppressed gene expression. However, skeletal muscle and lung tissues bucked this trend, demonstrating age-related demethylation instead.
The density of age-associated DMPs varied dramatically between tissues. Brain, liver, lung, skeletal muscle, and skin showed abundant DMPs, suggesting these tissues undergo significant epigenetic reconfiguration during aging. In contrast, kidney, prostate, rectum, and stomach exhibited fewer DMPs, which possibly reflecting greater epigenetic stability or limitations in sample size.
The density of age-associated DMPs varied dramatically between tissues. Brain, liver, lung, skeletal muscle, and skin showed abundant DMPs, suggesting these tissues undergo significant epigenetic reconfiguration during aging. In contrast, kidney, prostate, rectum, and stomach exhibited fewer DMPs, which possibly reflecting greater epigenetic stability or limitations in sample size.
Universal Biomarkers and Therapeutic Targets
Among the most significant findings were several genes whose methylation status serves as powerful aging biomarkers across multiple tissues:
· Developmental regulators HDAC4 and HOX: Previously known to be involved in age-related changes
· MEST gene: Associated with diabetes and obesity
· Protocadherin gamma (PCDHG) family: Showed increased methylation across diverse tissues
Protocadherins play crucial roles in cell adhesion and intracellular signaling, maintaining tissue structural and signaling stability. Prior research has linked PCDHG hypermethylation to reduced white matter volume in the brain, suggesting a mechanism connecting epigenetic changes to neurological aging.
Notably, several CpG sites previously identified as tissue-specific biomarkers (in genes ELOVL2, KLF14, FHL2, TBR1, and TRIM59) emerged as pan-tissue aging markers, revealing unexpected commonalities in the aging process across different organ systems.
· Developmental regulators HDAC4 and HOX: Previously known to be involved in age-related changes
· MEST gene: Associated with diabetes and obesity
· Protocadherin gamma (PCDHG) family: Showed increased methylation across diverse tissues
Protocadherins play crucial roles in cell adhesion and intracellular signaling, maintaining tissue structural and signaling stability. Prior research has linked PCDHG hypermethylation to reduced white matter volume in the brain, suggesting a mechanism connecting epigenetic changes to neurological aging.
Notably, several CpG sites previously identified as tissue-specific biomarkers (in genes ELOVL2, KLF14, FHL2, TBR1, and TRIM59) emerged as pan-tissue aging markers, revealing unexpected commonalities in the aging process across different organ systems.
From Biomarkers to Therapeutic Interventions
Unlike traditional epigenetic clocks that treat methylation merely as an age indicator, this research focuses on the functional significance of age-related methylation changes. Most identified changes appear to contribute to age-related decline, though some may serve protective functions.
Particular promise lies in the connection between methylation patterns and NAD⁺ metabolism. The researchers highlight the NAD⁺ biosynthesis pathway via nicotinamide riboside utilization as a potential therapeutic target. NAD⁺ is essential for healthy aging, with declining levels associated with mitochondrial dysfunction and increased DNA damage. Restoring NAD⁺ levels, potentially through nicotinamide riboside supplementation, may counteract age-related changes—a hypothesis supported by emerging clinical evidence.
Particular promise lies in the connection between methylation patterns and NAD⁺ metabolism. The researchers highlight the NAD⁺ biosynthesis pathway via nicotinamide riboside utilization as a potential therapeutic target. NAD⁺ is essential for healthy aging, with declining levels associated with mitochondrial dysfunction and increased DNA damage. Restoring NAD⁺ levels, potentially through nicotinamide riboside supplementation, may counteract age-related changes—a hypothesis supported by emerging clinical evidence.
Limitations and Future Directions
Despite its scale, this study represents just the beginning. As Holger Bischoff, an epigeneticist at the Leibniz Institute for Aging, notes, the human genome contains approximately 30 million epigenetically modified sites—meaning even this extensive analysis captures only a fraction of the complete picture.
Nevertheless, the publicly available epigenetic atlas of aging-related markers provides an invaluable resource for future research. It confirms that aging involves not just random methylation errors but systematic, tissue-specific, and often directional remodeling of the methylome—impacting pathways involved in cellular development, synaptic structure, cytoskeletal integrity, and immune regulation.
This comprehensive map doesn't just tell us how old we are—it reveals how our cells age and points toward potential interventions. As researchers continue to decode this epigenetic language of aging, we move closer to developing targeted therapies that could extend healthspan by addressing the fundamental mechanisms of biological aging. The clock is ticking, but for the first time, we're beginning to understand its intricate mechanism and how we might one day reset it.
Nevertheless, the publicly available epigenetic atlas of aging-related markers provides an invaluable resource for future research. It confirms that aging involves not just random methylation errors but systematic, tissue-specific, and often directional remodeling of the methylome—impacting pathways involved in cellular development, synaptic structure, cytoskeletal integrity, and immune regulation.
This comprehensive map doesn't just tell us how old we are—it reveals how our cells age and points toward potential interventions. As researchers continue to decode this epigenetic language of aging, we move closer to developing targeted therapies that could extend healthspan by addressing the fundamental mechanisms of biological aging. The clock is ticking, but for the first time, we're beginning to understand its intricate mechanism and how we might one day reset it.
Publication date: 28.08.2025
Source:
Eynon N. et al. DNA Methylation Ageing Atlas Across 17 Human Tissues. Research Square preprint. 2025 Aug. doi: 10.21203/rs.3.rs-7184037/v1
https://www.researchsquare.com/article/rs-7184037/v1
Source:
Eynon N. et al. DNA Methylation Ageing Atlas Across 17 Human Tissues. Research Square preprint. 2025 Aug. doi: 10.21203/rs.3.rs-7184037/v1
https://www.researchsquare.com/article/rs-7184037/v1